NASCAR DRIVER BRIAN VICKERS EXPERIENCING RECURRENT BLOOD CLOTS
NASCAR driver Brian Vickers will be missing the Sprint Cup Series race as a result of his ongoing struggle with recurrent blood clots. He had been scheduled to race this upcoming weekend, but suddenly began experiencing symptoms of blood clots on Thursday evening...
ANNOUNCING NATF'S 10TH ANNIVERSARY SIGNATURE EVENT
NATF's next Signature Event is scheduled to coincide with our 10th anniversary, and will take place on Thursday, March 10, 2016 at the Mandarin Oriental Hotel in Boston. Please mark your calendars for this special event!
2015 THROMBOSIS SUMMIT
Saturday, September 26
7:30 AM - 12:00 PM
Fairmont Copley Plaza Hotel, Boston
The 2015 Thrombosis Summit provides the latest innovations in testing, diagnosis, and treatment of thrombotic disorders. Sessions are led by national and local experts, who provide in-depth guidance on acute coronary syndromes, stroke in atrial fibrillation, and venous thromboembolism, as well as incorporating these cutting-edge techniques into practice.
Healthcare providers can earn up to 3.5 CME credits for attendance at the program.
AC FORUM ANTICOAGULATION BOOT CAMP
Join the Anticoagulation Forum for their 3rd Anticoagulation Boot Camp, July 23rd and 24th, 2015 in Boston. This compact 2-day conference offers comprehensive learning for those new to anticoagulation or a refresher on updates on the changing practice of anticoagulation.
Expert faculty will provide an interactive setting in a small group learning model with plenty of time for Q&A and dynamic discussion. Nursing and pharmacy CE credits will be provided.
Prior programs have sold out so register soon to secure your spot.
DVT/PE TREATMENT OPTIONS
How do healthcare providers decide which treatments are the best option for their patients? Read this article to find out more about DVT/PE treatment goals, options, risks, and decision-making.
For many years, Warfarin was the only oral anticoagulant commonly used to treat blood clots. In the past five years, the FDA has approved four new oral anticoagulants for the treatment of DVT, PE, and SPAF. Find out the differences between the five FDA-approved oral anticoagulants.